Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™)

Abstract

Pertussis continues to circulate in chinese communities and older children, adolescents and adults are sources of infection for unprotected infants. Two studies conducted in Jiangsu Province in the People's Republic of china assessed the immunogenicity, reactogenicity and safety of Boostrix™, a combined reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) when administered as a booster dose to children 6 to 8 years of age. Immunogenicity was assessed before and one month after vaccination in a subset. Reactogenicity was assessed over a 4-day follow-up using diary cards. a total of 690 chinese subjects were enrolled. Boostrix™ was well tolerated. One month after the booster dose, 100% of dTpa recipients had seroprotective antibody concentrations against diphtheria and tetanus. The percentage of subjects with a response against pertussis antigens (using locally defined cut-offs) was 91.9% for pertussis toxoid, 98.8% for filamentous hemagglutinin, and 100% for pertactin. The exploratory analysis showed no statistically significant differences between dTpa or diphtheria-tetanus vaccine in terms of the percentage of subjects with seroprotective antibodies against diphtheria or tetanus. These studies demonstrate that Boostrix™ is well tolerated and immunogenic when administered as a booster dose to 6 to 8 year old chinese children previously immunized with a combined diphtheriatetanus-pertussis vaccine. Introduction of dTpa into the routine chinese immunization schedule would provide booster vaccination against pertussis without the addition of further injections into the chinese vaccination schedule and is likely to promote improved pertussis control in older children. © 2010 Landes Bioscience.